Guo Guangchang: Fosun Strives to Break Through in Advantageous Sectors and Reach the Global Pinnacle

HONG KONG, Aug. 29, 2025 /PRNewswire/ -- On the morning of 29 August, Guo Guangchang, Chairman of Fosun International, stated at the Company's 2025 interim results presentation that Fosun will continue to increase investment in biopharmaceuticals and focus on deepening and thoroughly developing its advantageous industries to secure a commanding global position.

The interim results presentation was held in Shanghai this morning, with attendees including Chairman Guo Guangchang, Co-Chairman Wang Qunbin, Co-CEO Chen Qiyu, Co-CEO Xu Xiaoliang, CFO Gong Ping, along with numerous investors and analysts.

Guo Guangchang highlighted that Fosun achieved significant breakthroughs across several business segments in the first half of 2025, particularly in the biopharmaceutical segment. Moving forward, Fosun will seize growth opportunities and aim for breakthrough progress through technology innovation.

Regarding investor concerns about innovative drug R&D, Guo Guangchang explained that within Fosun's robust pipeline, it has reserved a batch of important products. Fosun's pharmaceutical innovation will extend beyond just Henlius. It also has Fosun Kite's CAR-T therapy, along with innovative drugs from its established product divisions, all of which have immense potential.

Guo Guangchang said, "I have ...